U.S. markets close in 56 minutes
  • S&P 500

    4,393.82
    +39.63 (+0.91%)
     
  • Dow 30

    34,278.07
    +358.23 (+1.06%)
     
  • Nasdaq

    14,867.99
    +121.60 (+0.82%)
     
  • Russell 2000

    2,222.92
    +36.74 (+1.68%)
     
  • Crude Oil

    71.97
    +1.48 (+2.10%)
     
  • Gold

    1,770.00
    -8.20 (-0.46%)
     
  • Silver

    22.72
    +0.11 (+0.48%)
     
  • EUR/USD

    1.1688
    -0.0043 (-0.36%)
     
  • 10-Yr Bond

    1.3260
    +0.0020 (+0.15%)
     
  • GBP/USD

    1.3611
    -0.0053 (-0.39%)
     
  • USD/JPY

    109.8890
    +0.6690 (+0.61%)
     
  • BTC-USD

    43,207.10
    +907.55 (+2.15%)
     
  • CMC Crypto 200

    1,082.83
    +42.34 (+4.07%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Amgen to pay up to $1.6 billion to acquire the privately held Teneobio

·1 min read
Amgen to pay up to $1.6 billion to acquire the privately held Teneobio
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Amgen Inc. were down 0.1% in premarket trading on Wednesday, the day after the company announced that it will pay up to $1.6 billion to buy TeneoBio, a privately held biotechnology company. Amgen is paying $900 million upfront, though potential milestone payments could push the deal's value up to $1.6 billion. TeneoBio is developing antibody technologies that include one therapy, currently in a Phase 1 clinical trial, aimed at treating certain forms of metastatic prostate cancer. The d